Amyloid-β Peptides Stimulate the Expression of the p75NTR Neurotrophin Receptor in SHSY5Y Human Neuroblastoma Cells and AD Transgenic Mice
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The progression toward end-stage Alzheimer's disease (AD) in the aging brain is driven by accumulating amyloid-beta (Abeta)(1-42) oligomers that is accompanied by the downregulation of the Trk A neurotrophin receptor and by either upregulation or at least maintenance of the p75 neurotrophin receptor (p75(NTR)), which can be stimulated by the accumulating Abeta(1-42) peptides. Here we show that Abeta(1-42) and its active fragment Abeta(25-35), but not Abeta(42-1), can at least double the level of p75(NTR) receptors in the membranes of model SH-SY5Y human neuroblastoma cells. We also show that p75(NTR) is upregulated in the hippocampi of two strains of AD transgenic mice. Specifically, the level of the p75(NTR) receptor in the hippocampal membranes from 12-15 month old AD-triple transgenic mice (3xTg-AD) harboring PS1 (M146V), AbetaPP (Swe), and tau (P301L) was nearly twice that in hippocampal membranes from age-matched wild-type mice. Similarly, the level of p75 (NTR) receptor in 7 month-old B6.Cg-Tg AD mice harboring PSEN1dE9 and AbetaPP (Swe) was also increased above the level in the corresponding wild-type mice. This increase correlated with the age-dependent rise in Abeta(1-42) levels in the AD mice. Thus, it appears that it could be the accumulating Abeta(1-42) that increases or at least prevents the downregulation of p75 (NTR) receptors in key parts of AD brains. It is possible that when the Abeta (1-42) accumulation reaches a critical level in the brain on the way to late-onset AD, the Abeta (1-42) induced p75 (NTR) receptor signaling starts a vicious cycle that accelerates AD development because of the activated receptors' recently shown ability to stimulate Abeta(1-42) production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
Self-citationSoluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 3×
“In addition to Aβ1−42 accumulation, there is also a time- and Aβ1−42-dependent increase in tau pathology (tau hyperphosphorylation and neurofibrillary tangle formation) in these transgenic animals’ brains [25,26], which is an another hallmark of AD.”
A Dynamic Relationship between Intracellular and Extracellular Pools of Aβ
Oddo, S., Caccamo, A., Smith, I. F., Green, K. N., & LaFerla, F. M. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050593 · Cited by 261
Self-citation
Cited by
Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease
Tu, S., Okamoto, S.-I., Lipton, S. A., & Xu, H. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-48 · Cited by 576
Armato, U., Chiarini, A., Chakravarthy, B., Chioffi, F., Pacchiana, R., Colarusso, E., Whitfield, J. F., & Dal Prà, I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.020 · Cited by 68
Self-citationNeurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm
Josephy-Hernandez, S., Jmaeff, S., Pirvulescu, I., Aboulkassim, T., & Saragovi, H. U. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.004 · Cited by 54
Chakravarthy, B., Gaudet, C., Ménard, M., Brown, L., Atkinson, T., LaFerla, F. M., Ito, S., Armato, U., Dal Prà, I., & Whitfield, J. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.09.056 · Cited by 52
Self-citationWang, Q., Wang, Y., Zhang, T., Jiao, S., Liu, Y., Zeng, F., Li, J., Yao, X., Zhou, H., Zhou, X., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13616 · Cited by 41
“Alternatively, p75ECD may reduce the amyloidogensis promoted by neurodegenerative ligands such as Ab and proneurotrophins via activation of p75NTR signaling pathways (Costantini et al. 2005; Chakravarthy et al. 2010).”
Background
Metadata
- Authors
- Chakravarthy, B., Gaudet, C., Ménard, M., Atkinson, T., Brown, L., LaFerla, F. M., Armato, U., & Whitfield, J.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-01-28
- Volume
- 19
- Issue
- 3
- Pages
- 915-925
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1716821397
- Cited by
- 85
- References
- 5
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyloid-β Peptides Stimulate the Expression of the p75NTR Neurotrophin Receptor in SHSY5Y Human Neuroblastoma Cells and AD Transgenic Mice. https://app.cochat.ai/papers/10.3233/jad-2010-1288
- The paper
- Chakravarthy, B., Gaudet, C., Ménard, M., Atkinson, T., Brown, L., LaFerla, F. M., Armato, U., & Whitfield, J. (2010). Amyloid-β Peptides Stimulate the Expression of the p75NTR Neurotrophin Receptor in SHSY5Y Human Neuroblastoma Cells and AD Transgenic Mice. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2010-1288
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.